MAYTANSINE

MAYTANSINE is a lipid of Polyketides (PK) class. Maytansine is associated with abnormalities such as Myelosuppression and BOSLEY-SALIH-ALORAINY SYNDROME. The involved functions are known as Mutation, Agent, Polymerization, Cell Cycle Arrest and Drug Kinetics. Maytansine often locates in Cytoplasm, Hepatic, Lysosomes, Cell surface and Microtubules. The associated genes with MAYTANSINE are ABCB1 gene, HM13 gene, CNN1 gene, CYP2C8 gene and CYP2D6 gene. The related lipids are Valerates. The related experimental models are Xenograft Model.

Cross Reference

Introduction

To understand associated biological information of MAYTANSINE, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with MAYTANSINE?

MAYTANSINE is suspected in Myelosuppression, BOSLEY-SALIH-ALORAINY SYNDROME and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with MAYTANSINE

MeSH term MeSH ID Detail
Breast Neoplasms D001943 24 associated lipids
Lung Neoplasms D008175 171 associated lipids
Pancreatic Neoplasms D010190 77 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Body Weight D001835 333 associated lipids
Prostatic Neoplasms D011471 126 associated lipids
Melanoma D008545 69 associated lipids
Brain Diseases D001927 27 associated lipids
Leukemia P388 D007941 43 associated lipids
Hyperplasia D006965 34 associated lipids
Leukemia D007938 74 associated lipids
Leukemia, Myeloid D007951 52 associated lipids
Bronchial Spasm D001986 18 associated lipids
Lymphoma, B-Cell D016393 24 associated lipids
Asthenia D001247 5 associated lipids
Hypopharyngeal Neoplasms D007012 1 associated lipids
Per page 10 20 | Total 17

PubChem Associated disorders and diseases

What pathways are associated with MAYTANSINE

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with MAYTANSINE?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with MAYTANSINE?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with MAYTANSINE?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with MAYTANSINE?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with MAYTANSINE?

Xenograft Model

Xenograft Model are used in the study 'IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.' (Ab O et al., 2015).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with MAYTANSINE

Download all related citations
Per page 10 20 50 100 | Total 611
Authors Title Published Journal PubMed Link
pmid:
Khot A et al. Development of a Translational Physiologically Based Pharmacokinetic Model for Antibody-Drug Conjugates: a Case Study with T-DM1. 2017 AAPS J pmid:28808917
Bender B et al. A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer. 2014 AAPS J pmid:24917179
Ait-Oudhia S et al. A Mechanism-Based PK/PD Model for Hematological Toxicities Induced by Antibody-Drug Conjugates. 2017 AAPS J pmid:28646408
Loebrich S et al. Development and Characterization of a Neutralizing Anti-idiotype Antibody Against Mirvetuximab for Analysis of Clinical Samples. 2017 AAPS J pmid:28534292
Singh AP and Shah DK Application of a PK-PD Modeling and Simulation-Based Strategy for Clinical Translation of Antibody-Drug Conjugates: a Case Study with Trastuzumab Emtansine (T-DM1). 2017 AAPS J pmid:28374319
Erickson HK and Lambert JM ADME of antibody-maytansinoid conjugates. 2012 AAPS J pmid:22875610
Cilliers C et al. Multiscale Modeling of Antibody-Drug Conjugates: Connecting Tissue and Cellular Distribution to Whole Animal Pharmacokinetics and Potential Implications for Efficacy. 2016 AAPS J pmid:27287046
Singh AP et al. Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1). 2016 AAPS J pmid:27029797
Maass KF et al. Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design. 2016 AAPS J pmid:26912181
Chari RV Targeted cancer therapy: conferring specificity to cytotoxic drugs. 2008 Acc. Chem. Res. pmid:17705444
Kim SU et al. Neurofibrillary degeneration in cultured adult mouse neurons induced by maytansine. 1980 Acta Neuropathol. pmid:7435167
Kolarich AR et al. Ado-trastuzamab emtansine associated hyponatremia and intracranial hemorrhage. 2014 Acta Oncol pmid:24834794
Dymowski W and Furmanowa M [Investigating cytostatic substances in tissue of plants Maytenus Molina in in-vitro cultures. II. chromatographic test of extracts from callus of Maytenus wallichiana R. et B]. 1990 Acta Pol Pharm pmid:1669332
Lambert JM and Morris CQ Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review. 2017 Adv Ther pmid:28361465
Friedkin M and Rozengurt E The role of cytoplasmic microtubules in the regulation of the activity of peptide growth factors. 1980 Adv. Enzyme Regul. pmid:7039258
Patel KC et al. Ado-trastuzumab emtansine for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer. 2014 Am J Health Syst Pharm pmid:24644113
Traynor K Ado-trastuzumab emtansine approved for advanced breast cancer. 2013 Am J Health Syst Pharm pmid:23515502
Muzaffar M et al. Acute Pancreatitis Associated With Ado-Trastuzumab Emtansine. Am J Ther pmid:25756468
Esteva FJ et al. What Can We Learn about Antibody-Drug Conjugates from the T-DM1 Experience? 2015 Am Soc Clin Oncol Educ Book pmid:25993162
Stinchcombe TE Novel formulations and new mechanisms of delivering chemotherapy. 2014 Am Soc Clin Oncol Educ Book pmid:24857128
Martin M and López-Tarruella S Emerging Therapeutic Options for HER2-Positive Breast Cancer. 2016 Am Soc Clin Oncol Educ Book pmid:27249772
Thigpen JT et al. Phase II study of maytansine in the treatment of advanced or recurrent adenocarcinoma of the ovary. A Gynecologic Oncology Group study. 1983 Am. J. Clin. Oncol. pmid:6846245
Thigpen JT et al. Phase II study of maytansine in the treatment of advanced or recurrent squamous cell carcinoma of the cervix. A Gynecologic Oncology Group study. 1983 Am. J. Clin. Oncol. pmid:6869315
Borden EC et al. Phase II evaluation of dibromodulcitol, ICRF-159, and maytansine for sarcomas. 1982 Am. J. Clin. Oncol. pmid:6956236
Slavik M et al. Phase II studies in advanced, recurrent pelvic malignancies: conducted by the Gynecologic Oncology Group, Experimental Design and Experience. 1982 Am. J. Clin. Oncol. pmid:6897490
Ravry MJ et al. Phase II evaluation of maytansine (NSC 153858) in advanced cancer. A Southeastern Cancer Study Group trial. 1985 Am. J. Clin. Oncol. pmid:3834790
Fleming MS et al. A reversed-phase high-performance liquid chromatography method for analysis of monoclonal antibody-maytansinoid immunoconjugates. 2005 Anal. Biochem. pmid:15840500
Luo Q et al. Structural Characterization of a Monoclonal Antibody-Maytansinoid Immunoconjugate. 2016 Anal. Chem. pmid:26629796
Sang H et al. Conjugation site analysis of antibody-drug-conjugates (ADCs) by signature ion fingerprinting and normalized area quantitation approach using nano-liquid chromatography coupled to high resolution mass spectrometry. 2017 Anal. Chim. Acta pmid:28088282
Eichner S et al. The interplay between mutasynthesis and semisynthesis: generation and evaluation of an ansamitocin library. 2012 Angew. Chem. Int. Ed. Engl. pmid:22135226
Monneret C [Current impact of natural products in the discovery of anticancer drugs]. 2010 Ann Pharm Fr pmid:20637355
Corrigan PA et al. Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate. 2014 Ann Pharmacother pmid:25082874
Leal M et al. Antibody-drug conjugates: an emerging modality for the treatment of cancer. 2014 Ann. N. Y. Acad. Sci. pmid:25123209
Luduena RF et al. Interactions of vinblastine and maytansine with tubulin. 1986 Ann. N. Y. Acad. Sci. pmid:3460446
Krop IE et al. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. 2015 Ann. Oncol. pmid:25355722
Martin M et al. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study. 2016 Ann. Oncol. pmid:27052654
Gebhart G et al. Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. 2016 Ann. Oncol. pmid:26598545
Foglietta J et al. Letter to the editor concerning 'Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA'. 2015 Ann. Oncol. pmid:25632067
Olson EM et al. Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer. 2012 Ann. Oncol. pmid:21531783
Sibaud V et al. T-DM1-related telangiectasias: a potential role in secondary bleeding events. 2015 Ann. Oncol. pmid:25403586
Gradishar WJ Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab. 2013 Ann. Oncol. pmid:23827380
Wall ME and Wani MC Antineoplastic agents from plants. 1977 Annu. Rev. Pharmacol. Toxicol. pmid:326159
Maslin DN [Ansamycins]. 1979 Antibiotiki pmid:37801
Mescher C et al. Left Ventricular Ejection Fraction Screening and Clinical Decision-making in Metastatic HER2-positive Breast Cancer. 2017 Anticancer Res. pmid:28668870
Michel LL et al. T-DM1 as a New Treatment Option for Patients with Metastatic HER2-positive Breast Cancer in Clinical Practice. 2015 Anticancer Res. pmid:26254411
Tanida S et al. Inhibition of cilia regeneration of Tetrahymena by ansamitocins, new antitumor antibiotics. 1979 Antimicrob. Agents Chemother. pmid:475367
Hanka LJ and Barnett MS Microbiological assays and bioautography of maytansine and its homologues. 1974 Antimicrob. Agents Chemother. pmid:15825322
Zhao M et al. Effects of the Methylmalonyl-CoA Metabolic Pathway on Ansamitocin Production in Actinosynnema pretiosum. 2017 Appl. Biochem. Biotechnol. pmid:27787765
Li T et al. Improvement of ansamitocin P-3 production by Actinosynnema mirum with fructose as the sole carbon source. 2015 Appl. Biochem. Biotechnol. pmid:25564203